Differential (Click to cross reference) acoustic neurinoma adverse drug reaction bevacizumab cerebrovascular accident chemotherapy, CNS treatment and complications with complications drug induced neurologic disorders efficacy encephalopathy, delayed epistaxis erythropoietin erythropoietin treatment glioblastoma multiforme(astrocytoma Gr.III) glioma hearing loss hormone replacement hypertension iatrogenic neurologic disorders immunosuppressive agents intracerebral hemorrhage leukoencephalopathy life expectancy monoclonal antibodies MRI, abnormal MRI, diffusion weighted MRI, disappearing lesion on neoplasm, primary intracerebral neoplasm, primary of CNS neoplasm, primary of CNS-survival neoplasm, primary of CNS-treatment of neurofibromatosis 2 oral contraceptives oral contraceptives, cerbrovascular disease and pontine hemorrhage posterior leukoencephalopathy syndrome premarin prognosis review article risk-benefit assessment safety schwannoma strokelike episodes subarachnoid hemorrhage tamoxifen treatment of neurologic disorder vascular endothelial growth factor white matter disease

Showing articles 0 to 6 of 6 Drugs Associated with Ischemic Stroke Stroke 52:e646-e659, Marto, J.P.,et al, 2021 Bevacizumab in Glioblastoma - Still Much to Learn NEJM 370:764-765, Fine, H.A., 2014 Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas are Associated with Improved Survival Compared with Matched Controls AJNR 33:1763-1770, Mong, S.,et al, 2012 Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2 NEJM 361:358-367, Plotkin,S.R.,et al, 2009 Intracranial Hemorrhage in Patients Treated with Bevacizumab and Low-Molecular Weight Heparin Clin Adv Hematol Oncol 5:375-379, Nguyen, T.D.,et al, 2007 Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab NEJM 354:980-982, Ozcan,C.,et al, 2006 Showing articles 0 to 6 of 6